Events April 28, 2020, 12:00 PM - 1:00 PM ET

Jumpstart Bio: Future Generic Challenge for Early Small Molecule Innovators: Maximizing Exclusivity through Patent and Regulatory Strategy

In this new "normal" we're taking our Jumpstart Bio series to the web! Our Jumpstart Bio webinar series equips drug development and commercialization professionals to anticipate, prepare for, and respond to issues on the horizon for the industry.

Join Goodwin’s senior patent prosecution partner Theresa Kavanaugh will provide an in-depth and timely overview – for clinical stage and pre-clinical companies - of how and when generic drug companies can enter the U.S. market by challenging innovator patents and how early planning can help patent and regulatory strategy. Drawing on Theresa’s extensive experience developing small molecule patent portfolios for early stage companies (that have later provided substantial market exclusivity upon FDA approval), this program will analyze patent strategies that have been successful in defending against generic challenges. Our partners will also provide real world examples of patent strategies that innovators can and should be considering as their small molecule compounds proceed from the lab through clinical trials.

1.0 Hour of CA and NY CLE Credit Available.